Tandem Diabetes Care TNDM Supplies and other — Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's supplies and other — sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's supplies and other — sales?
- Tandem Diabetes Care (TNDM) reported supplies and other — sales of $136.8M in Q1 2026.
- How has Tandem Diabetes Care's supplies and other — sales changed year-over-year?
- Tandem Diabetes Care's supplies and other — sales increased by 3.4% year-over-year, from $132.3M to $136.8M.
- What is the long-term trend for Tandem Diabetes Care's supplies and other — sales?
- Over 3 years (2022 to 2025), Tandem Diabetes Care's supplies and other — sales has grown at a 13.9% compound annual growth rate (CAGR), from $372.86M to $550.57M.
- What does supplies and other — sales mean?
- This metric represents the revenue generated from the sale of recurring consumables, accessories, and associated services required to support the primary hardware platform. It serves as a critical indicator of the installed base size and long-term customer retention, as these items are essential for the ongoing operation of the company's medical devices. Growth in this segment reflects the recurring nature of the business model and the deepening of the relationship with the existing patient population.